Jack Allen
Stock Analyst at Baird
(0.88)
# 3,934
Out of 5,055 analysts
42
Total ratings
36.36%
Success rate
-14.35%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jack Allen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRSP CRISPR Therapeutics AG | Maintains: Neutral | $52 → $44 | $55.32 | -20.46% | 3 | Nov 11, 2025 | |
| VOR Vor Biopharma | Upgrades: Outperform | $20 → $64 | $10.02 | +538.72% | 5 | Oct 15, 2025 | |
| TSHA Taysha Gene Therapies | Maintains: Outperform | $7 → $12 | $4.12 | +191.26% | 5 | Oct 2, 2025 | |
| FATE Fate Therapeutics | Maintains: Neutral | $5 → $4 | $0.97 | +311.10% | 2 | May 14, 2025 | |
| ALLO Allogene Therapeutics | Maintains: Outperform | $12 → $9 | $1.23 | +631.71% | 3 | May 14, 2025 | |
| INKT MiNK Therapeutics | Maintains: Outperform | $80 → $40 | $12.00 | +233.33% | 2 | Nov 15, 2024 | |
| ACLX Arcellx | Maintains: Outperform | $77 → $106 | $90.34 | +17.33% | 5 | Nov 6, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Neutral | $24 → $18 | $8.48 | +112.26% | 2 | Oct 25, 2024 | |
| TIL Instil Bio | Reiterates: Outperform | $180 | $12.77 | +1,309.55% | 9 | Sep 16, 2024 | |
| MREO Mereo BioPharma Group | Initiates: Outperform | $8 | $1.77 | +351.98% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $84 | $36.57 | +129.70% | 1 | Oct 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $1.74 | +187.36% | 1 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $4.14 | - | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $6 → $9 | $4.11 | +118.98% | 1 | Oct 7, 2021 |
CRISPR Therapeutics AG
Nov 11, 2025
Maintains: Neutral
Price Target: $52 → $44
Current: $55.32
Upside: -20.46%
Vor Biopharma
Oct 15, 2025
Upgrades: Outperform
Price Target: $20 → $64
Current: $10.02
Upside: +538.72%
Taysha Gene Therapies
Oct 2, 2025
Maintains: Outperform
Price Target: $7 → $12
Current: $4.12
Upside: +191.26%
Fate Therapeutics
May 14, 2025
Maintains: Neutral
Price Target: $5 → $4
Current: $0.97
Upside: +311.10%
Allogene Therapeutics
May 14, 2025
Maintains: Outperform
Price Target: $12 → $9
Current: $1.23
Upside: +631.71%
MiNK Therapeutics
Nov 15, 2024
Maintains: Outperform
Price Target: $80 → $40
Current: $12.00
Upside: +233.33%
Arcellx
Nov 6, 2024
Maintains: Outperform
Price Target: $77 → $106
Current: $90.34
Upside: +17.33%
Intellia Therapeutics
Oct 25, 2024
Maintains: Neutral
Price Target: $24 → $18
Current: $8.48
Upside: +112.26%
Instil Bio
Sep 16, 2024
Reiterates: Outperform
Price Target: $180
Current: $12.77
Upside: +1,309.55%
Mereo BioPharma Group
Jun 13, 2024
Initiates: Outperform
Price Target: $8
Current: $1.77
Upside: +351.98%
Oct 31, 2023
Initiates: Outperform
Price Target: $84
Current: $36.57
Upside: +129.70%
Nov 2, 2022
Initiates: Outperform
Price Target: $5
Current: $1.74
Upside: +187.36%
May 18, 2022
Upgrades: Outperform
Price Target: n/a
Current: $4.14
Upside: -
Oct 7, 2021
Upgrades: Outperform
Price Target: $6 → $9
Current: $4.11
Upside: +118.98%